AtriCure, Inc. 10-Q Summary: Quarter Ended September 30, 2007
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for AtriCure, Inc., a medical device company focused on the surgical treatment of atrial fibrillation. The report covers the three and nine months ended September 30, 2007. The Company develops and sells the Isolator bipolar ablation system and related devices. International sales accounted for approximately 15% of total revenue for the nine-month period.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2007 | Nine Months Ended Sept 30, 2007 |
|---|---|---|
| Revenues | $12,054,459 | $35,157,448 |
| Gross Profit | $9,294,041 (77.1% margin) | $27,639,382 (78.6% margin) |
| Net Loss | $(2,598,176) | $(9,687,685) |
| Loss Per Share (Basic/Diluted) | $(0.18) | $(0.74) |
| Cash and Cash Equivalents | $17,230,239 (as of Sept 30, 2007) | |
| Short-term Investments | $3,979,050 (as of Sept 30, 2007) | |
| Total Debt (Current + Long-term) | $797,268 (as of Sept 30, 2007) | |
| Working Capital | $26,597,061 (as of Sept 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 28.8% for the quarter and 27.2% for the nine-month period compared to the prior year, driven by higher unit sales and average selling prices.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased significantly ($2.1M for the quarter; $6.4M for nine months) due to headcount expansion in sales/marketing and increased stock-based compensation. Research and development expenses decreased ($0.8M for the quarter; $0.6M for nine months) due to reduced clinical trial activities and redeployment of staff.
- Acquisition: In August 2007, the Company acquired the Frigitronics CCS-200 product line for approximately $3.7 million, adding $2.4 million in goodwill and $0.5 million in intangible assets.
- Financing: In May 2007, the Company completed a private placement of common stock, raising net proceeds of $15.3 million.
Outlook, Risks, and Contingencies
- Clinical Trials: The FDA approved the ABLATE clinical trial (open-heart concomitant) and the RESTORE-SR II B trial (minimally invasive sole-therapy). The Company plans to file a PMA for open-heart AF approval following the ABLATE trial.
- Regulatory Status: The Isolator system received 510(k) clearance for cardiac tissue ablation. The left atrial appendage clip system is pending 510(k) clearance in the U.S. and is currently in European clinical trials.
- Litigation: A securities class action lawsuit (Levine v. AtriCure) remains pending; the Company's motion to dismiss was denied in September 2007, with a motion for reconsideration pending. The Company intends to vigorously defend the suit.
- Settlements: A legal dispute with former European distributor Life Support Technology (LST) was settled for approximately €257,360, recorded as a $0.3 million liability.
- Liquidity: Management believes current cash and investments ($21.2 million total) are sufficient to meet needs for at least the next 12 months.
Key Facts for Investor Verification
- Verify the timeline and enrollment status of the FDA-approved ABLATE and RESTORE-SR II B clinical trials, as future revenue growth depends on regulatory approval for AF treatment.
- Monitor the status of the pending securities class action lawsuit and the outcome of the motion for reconsideration.
- Assess the integration and revenue contribution of the newly acquired Frigitronics CCS-200 product line.
- Review the burn rate of cash given the continued net losses and the reliance on the May 2007 capital raise for working capital.
- Confirm the progress of the 510(k) application for the left atrial appendage clip system.